INOVIQ overview

Next-generation cancer diagnostics and therapeutics

Investor Day
LIFE SCIENCE
PART OF EMERGENCE2026

18th February 2026

INOVIQ

ASX: IIQ

Disclaimer

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

INOVIQ's mission is to transform patient lives through earlier cancer detection and more effective treatments, powered by proprietary exosome technologies



INOVIQ

INOVIQ's exosome technologies enable advanced diagnostics and therapeutics

Exosomes are the body's natural information-carrying nanoparticle — tiny packages released by all cells that transport *RNA, proteins and lipids* to communicate messages from the parent to recipient cells

- Window into disease for **Diagnostics**: Exosomes provide disease-specific information enabling earlier, more accurate detection from a simple blood test
- Enriched signals for **Precision Medicine**: Tumour-derived exosomes enable real-time insights across the cancer care continuum
- Targeted delivery vehicle for **Therapeutics**: Engineered exosomes deliver therapeutic payloads to specific tissues to target and destroy cancer



INOVIQ's platform isolates, reads and engineers exosomes for advanced diagnostics and therapeutics

INOVIQ is pioneering next-generation diagnostics and therapeutics that transform care cancer

- **Proprietary exosome platform** enables high-performance diagnostics and targeted exosome therapeutics
- Clinical-stage **EXO-OC™ ovarian cancer screening test** detects 100% early-stage disease in validation studies
- Preclinical **CAR-exosome therapeutic program** demonstrating strong early data in solid tumours
- Commercial **EXO-NET® exosome isolation tools** generating early revenue through Promega and other partners
- Leadership team and Advisory Board with expertise across **exosomes, diagnostics, cell therapy and commercialisation**
- **Well-funded** to advance pipeline to key catalysts and drive value in 2026

Financial snapshot (ASX:IIQ)	
Market capitalisation	A$46.5m
Share price (13 Feb 2026)	A$0.33
52-week H/L	A$0.690-0.32
Ordinary shares	140,775,458
Listed / Unlisted options	9,753,913 / 7,175,000
Cash (31 Dec 2025)	A$13.8m

Shareholder profile	
Top 20	35.0%
Board/KMP	4.2%
Institutional/Funds	11.6%

IIQ 12-month share price performance



EXO-OC™ Ovarian Cancer Screening Test

no approved test for early detection in asymptomatic, average-risk women

- Simple blood test for early detection of OC in asymptomatic average-risk women aged ~45-74
- 100% — Detected 100% of early-stage I & II ovarian cancers in 498-sample clinical validation study[2,3]
- Exceeds screening criteria – sensitivity ≥75% (low false -ve) & specificity ≥99.6% (min false +ve)[1]
- Designed to integrate and scale into high-throughput pathology laboratories
- Early detection could improve survival from ~30% to 95% [4]
- TAM >240M women every 2 years upon regulatory approval[5]

EXO-OC Overview

Patented **EXO-NET® technology** used to isolate exosomes

Combines **multiple exosomal miRNA + CA125 biomarkers** in a proprietary **AI-powered algorithm** to enable the *early and accurate detection of ovarian cancer*[6]

Detects 100% early-stage (I/II) & 77% all-stage (I-IV) ovarian cancers at 99.6% specificity

Protected by provisional **patent application and exclusive worldwide rights**[7,8]

Next Milestones

H1 CY2026 **Clinical Validation Study** results

H2 CY2026 **LDT ready & partnered**

H1 CY2027 **LDT launched** by US CLIA/CAP lab partner

2027 **Pivotal Clinical Trial** start

2029+ first **Regulatory Approval**

1. 2024 Apr 30;14(9):949. doi: 10.3390/diagnostics14090949;. 2. Salomon et al, Poster #5592 ASCO 2025; 3. EXO-OC miRNA validation study results (ASX: 2/6/25); 4. Cancer Research UK – Survival for ovarian cancer; 5. Based on eligible population in 9 major markets and breast mammography participation rates of ~60%; 6. AI/Machine Learning (ML) algorithms independently developed by leading computational scientist, Prof Amanda Barnard; 7. APPA filed on 29 May 2025; 8. INOVIQ-UQ Licence Agreement (ASX: 26/9/25)

EXO-OC™ | Development pathway for high-impact diagnostics



***CLIA** = Clinical Laboratory Improvement Amendments (US); **IVD** = In Vitro Diagnostic; **LDT** = Laboratory Developed Test; **NCCN** = National Comprehensive Cancer Network (US); **OC** = Ovarian Cancer*

CAR-Exosomes are a cell-free therapy to target and kill solid tumours



Cell-free therapy for treatment of solid tumours with potential cost, safety and efficacy advantages over autologous cell therapies

- **CAR-exosome therapy** to target and kill solid tumours
- **Platform technology** with multiple therapeutic applications
- **Targeting specificity:** EVs inherit precision targeting from engineered (CAR) parent immune cells
- **Anti-tumour efficacy:** Immune cell-derived EVs deliver cytotoxic molecules (granzymes, perforin) to kill tumours
- **Improved safety:** Reduced risk of immune rejection, cytokine release syndrome, CRES and GvHD
- **Lower cost:** Significantly improved cost, logistics and patient accessibility restores commercial viability compared to autologous CAR-T therapy (~US$500k)*

**Based on average price per patient for MAbs of US$165K pa (Cost and supply considerations for antibody therapeutics) and autologous CAR-T therapies of US$509K per dose (US Dept Veterans Affairs, National Acquisition Center CCST)*

CAR-Exosomes PoC achieved with positive efficacy and safety results

Positive *in vivo* PoC Results for CAR-NK-EVs in Triple-Negative Breast Cancer

Key Findings

Superior Tumour Inhibition
CAR-EVs reduced tumour burden by 61.5%

Outstanding Survival
100% survival of CAR-EV treated mice

Excellent Safety Profile
CAR-EVs well tolerated

Precision Targeting
CAR-EVs had reduced non-specific liver accumulation

VALIDATES EGFR-TARGETED CAR-EXOSOMES

"Compelling proof-of-concept for a novel therapeutic modality"
- Professor Greg Rice -

"Strong efficacy, excellent safety and precision targeting"
- Dr Leearne Hinch -

TNBC = Triple-Negative Breast Cancer; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; PoC = Proof of Concept;
1. CAR-NK-EV in vitro PoC (ASX: 18/6/25 & 22/9/25); 2. CAR-NK-EV in vivo PoC (ASX: 22/12/25)

INOVIQ

Future Catalysts| Driving growth and value across our pipeline

	Jul-25	Dec-25	Jun-26	Dec-26
EXO-NET (research tools)	• EXO-NET sales growth, collaborations & diagnostic partnering			
EXO-OC (OC screening)	✓ Commence clinical studies for OC screening	• Strategic partnering for LDT commercialisation *(underway)* • Progress IVD clinical & regulatory strategy • Clinical study data	• Analytical and clinical validation data • LDT ready & partnered	
CAR-Exosome (solid tumour Tx)	✓ In vivo efficacy data in TNBC model	• Progress manufacturing for future clinical trials • Preclinical CAR-EV TNBC & Ovarian Cancer studies	• Commence IND enabling studies	
Other/ pipeline expansion	• Neu5Gc test bead-based assay development, verification & validation studies, and partnering • Continue to evaluate strategic partnering and technology acquisition opportunities			

Exosome company with clinical-stage ovarian cancer screening test and early therapeutic program

Future milestones are forward-looking and may change based on study results, funding, partnering and priorities

INOVIQ

Summary| Positioned for growth

Leading exosome company with proven technology platform and best-in-class research tools, diagnostics and therapeutics

Exosome research tools partnered, on-market and generating initial revenue with potential for future licensing income

Clinical-stage EXO-OC screening test targeting significant unmet need in US$5.5B market

Preclinical CAR-exosome program with potential cost, safety & efficacy advantages over autologous cell therapy

Focus on partnering and strategic acquisitions to expedite commercialisation and growth

Significant upside potential in FY26 catalysts and ASX: IIQ share price

INOVIQ

Contacts

Dr Leearne Hinch BVMS MBA
Chief Executive Officer
e. lhinch@inoviq.com

Dr Emma Ball PhD MBA GAICD
Chief Commercial Officer
e. eball@inoviq.com

INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia
p. +61 3 9548 7586 | e. info@inoviq.com | w. www.inoviq.com

Appendices



Glossary

AUC	area under the curve
BC	breast cancer
CA125	cancer antigen 125 biomarker (used in ovarian cancer monitoring)
CA15-3	cancer antigen 15-3 biomarker (used in breast cancer monitoring)
CAGR	compound annual growth rate
CAR	chimeric antigen receptor
CDx	companion diagnostic (for therapeutic product)
CLIA	clinical laboratory improvement amendments (US regulatory standards)
CRES	CAR-related encephalopathy syndrome
CRO	contract research organization
ctDNA	circulating tumour DNA
Dx	diagnostic
EGFR	epidermal growth factor receptor
ER	estrogen receptor
EV	extracellular vesicle
GvHD	graft vs host disease
HER2	human epidermal growth factor receptor 2
HT	high throughput
ICC	immunocytochemistry
IDE	investigational device exemption (FDA)
IND	Investigational new drug
IVD	in vitro diagnostic
KOL	key opinion leader
LDT	laboratory developed test
MIA	in vitro multivariate index assay
MRD	minimal residual disease
MRI	magnetic resonance imaging
MSC	mesenchymal stem cell
NK	natural killer (cell)
OC	ovarian cancer
PMA	premarket approval (FDA)
PR	progesterone receptor
ROC	receiver operating characteristic curve
RUO	research use only
Se	Sensitivity is the percentage of correctly identified cases
SOC	standard of care
Sp	Specificity is the percentage of correctly identified controls
TAM	total addressable market
TNBC	triple negative breast cancer
TVUS	transvaginal ultrasound
Tx	therapeutic
UQ	The University of Queensland
US	United States

Leadership| Corporate, scientific, clinical and commercial expertise

DR LEEARNE HINCH BVMS MBA
Chief Executive Officer

Biotechnology CEO with a proven track record in corporate strategy, capital raising, product development, business development and partnering across diagnostics, medical devices, therapeutics and animal health.

Past leadership and consulting roles in ASX-listed biotechnology, multinational and private companies including Eustralis Pharmaceuticals, HealthLinx, OBJ, Holista Colltech, Chemeq, Virbac and Mars.

MARK EDWARDS BAcc CA
CFO & Company Secretary

Experienced finance executive with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions.

Previous senior roles in ASX listed pharmaceutical, medical device and healthcare companies, including Medical Developments International and Cogstate.

EMMA BALL PhD MBA GAICD
Chief Commercial Officer

Experienced biotechnology commercialisation executive with expertise in business development, licensing, and strategic partnerships across therapeutics, vaccines and diagnostics.

Currently Non-Executive Chair of BioMelbourne Network. Previous senior business development/ licensing roles in multinational biotechnology companies CSL Ltd and Illumina Inc.

PROF GREG RICE PhD MHA
Founding Scientist & Advisor

Globally recognised, award-winning scientist with over 35 years' experience and a successful track record in oncology research, exosome science, biomarker discovery, and diagnostics development.

Previous leadership roles in academia and industry including at The University of Queensland Centre for Clinical Research, Baker Heart Institute, University of Melbourne, Monash University and HealthLinx.

DR REBECCA LIM PhD
Chief Scientific Officer

Internationally recognised biotechnology executive with over 20 years' experience in translational research, clinical development and regulatory pathways for cell and gene therapies, regenerative medicine, and extracellular vesicle (EV) technologies.

She has led advanced therapy programs from preclinical stages to IND clearance and GMP manufacturing, with senior roles at US-based CTMC, Prescient Therapeutics (ASX:PTX) and Monash University to drive innovation in cell and exosome-based therapies.

Board| Capital markets, healthcare and biotech experience

PETER GUNZBURG
Non-Executive Chairman

Experienced public company director, stockbroker and investor with extensive leadership across listed markets.

Currently serves as Non-Executive Chairman of ASX listed Metals X Limited and Non-Executive Director of London Stock Exchange listed First Tin Plc.

Formerly a Director of the Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd, and BARD1 Life Sciences Ltd.

MAX JOHNSTON
Non-Executive Director

Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.

Currently NED Neurotech International. Previously President and CEO of Johnson & Johnson Pacific, Chairman of AusCann Ltd, NED of PolyNovo Ltd, Medical Developments International Ltd, Tissue Repair Ltd and CannPal Animal Therapeutics Ltd.

PHILIP POWELL
Non-Executive Director

Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.

Previously at OAMPS Ltd and Arthur Andersen, and NED at RMA Global Ltd, Polynovo Ltd and Medical Developments International Ltd.

DR GEOFF CUMMING
Non-Executive Director

Healthcare and biotechnology director with extensive diagnostics industry experience.

Currently NED AnteoTech Ltd.

Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre international Ltd and MD/CEO of Anteo Diagnostics Ltd.

MARY HARNEY
Non-Executive Director

Experienced Non-Executive Director and Chief Executive bringing a deep understanding of applied life science research, in addition to experience in biopharmaceutical regulatory affairs and commercialisation.

Current Chair of Oncology One Pty Ltd. Previously Chair of Race Oncology (ASX: RAC) and Microbio Limited.

EXO-OC™ | Ovarian cancer screening test

Exosome-based blood test in development for screening Ovarian Cancer in asymptomatic, average-risk women

- Patented **EXO-NET® technology** used to isolate exosomes
- Combines **multiple exosomal miRNA and CA125 biomarkers** in a proprietary **AI-enhanced ML algorithm** to enable the *early and accurate detection of ovarian cancer*[1]
- **Validated** in retrospective case-control study in 498 samples from age-matched normal healthy women and benign masses vs ovarian cancers[2,3]
- **Fully-automated**, **high-throughput test** compatible with existing clinical lab platforms and workflows
- EXO-OC test protected by provisional **patent application and exclusive worldwide rights**[4,5]

Meets screening performance criteria for the general population requiring sensitivity ≥ 75% and specificity ≥ 99.6% [6]



Set	Control	Benign	Stage I	Stage II	Stage III	Stage IV	na	Total
Training	161	119	21	3	41	21	6	372
Test	59	35	6	3	14	6	2	125

- ✓ **100% sensitivity for early-stage ovarian cancer** (I & II)
- ✓ **77% sensitivity at >99.6% specificity** across all stages (I – IV)

1. Machine Learning (ML) algorithms developed by leading computational scientist, Prof Amanda Barnard; 2. Salomon et al, Poster #5592 ASCO 2025; 3. EXO-OC miRNA validation study results (ASX: 2/6/25); 4. APPA filed on 29 May 2025; 5. INOVIQ-UQ Licence Agreement (ASX: 26/9/25); 6. 2024 Apr 30;14(9):949. doi: 10.3390/diagnostics14090949;

THE UNIVERSITY OF QUEENSLAND AUSTRALIA

INOVIQ

EXO-OC™ | Commercialisation strategy

Dual-path commercialisation strategy
to maximise speed, access and value for patients, clinicians & investors

	Laboratory Developed Test (LDT)	In Vitro Diagnostic (IVD)
Partner	**Laboratory partner** to offer testing service via single CLIA/CAP lab	**Large diagnostics company** for global scale to distribute EXO-OC kits & deliver through pathology networks
Launch	**LDT 2027** (US)	**IVD 2029+** post regulatory approvals (US, UK, Europe, China, Asia, Australia)
Adoption	**Peer reviewed publications** & presentations Build **KOL** network	**+ Pivotal Clinical Trial** (prospective, multi-centre) **+ Health economic** modelling & HTA **+ Clinical guideline** inclusion (USPSTF, NICE, NCCN, ACOG)
Reimbursement	**Patient-Pay** initially Builds evidence for reimbursement	**Public & Private payers** Medicare & Medicaid, Others
Advantages	**Fastest path-to-market** Early access for patients Early revenue Real-world data to support IVD filings	**Broader clinical adoption** Global market reach Sustainable growth Higher reimbursement & guideline potential

*CAP = College of American Pathologists; **CLIA** = Clinical Laboratory Improvement Amendments; HTA: Heath Technology Assessment; **IVD** = In Vitro Diagnostic; **LDT** = Laboratory Developed Test; **USPSTF** = US Preventative Services Task Force; **ACOG** = American College of Obstetricians & Gynecologists; **NCCN** = National Comprehensive Cancer Network*

EXO-OC™| Clinical and regulatory strategy

Intended use

- Screening test for Ovarian Cancer in **asymptomatic, average-risk women aged 45 - 74**

Retrospective clinical studies*

(sample collection commenced Oct-25)

- **Cohort:** stages I – IV Ovarian Cancer
- **Disease specificity:** other cancer types & inflammatory conditions
- **High-risk:** BRCA/Lynch/Family history

Partner validation studies in CLIA-certified/CAP-accredited lab

- **Analytical validation** to show accuracy & reproducibility
- **Clinical validation** to demonstrate sensitivity and specificity in intended use population



*Informed by discussions with potential partners; **BDD** = Breakthrough Device Designation; **CA125** = Cancer Antigen 125; **CAP** = College of American Pathologists; **CLIA** = Clinical Laboratory Improvement Amendments; **CRO** = Contract Research Organisation; **HGSOC** = High Grade Serous Ovarian Cancer; **IVD** = In Vitro Diagnostic; **LDT** = Laboratory Developed Test; **PMA** = Premarket Approval*

Ovarian Cancer in 9 Major Markets

Market	Incidence	Prevalence (5-year)	Eligible Population (45-74yo)[1]	General Screening Participation	Annual Addressable Population [11]
China	61,060	180,870	282,713,102	51.4% [2]	145,201,449
USA	21,179	68,388	60,689,385	75.7% [3]	45,941,864
Japan	10,693	33,732	24,907,722	46.9% [4]	11,681,721
Germany	7,547	21,475	17,197,363	51.0% [5]	8,770,655
UK	6,390	19,325	12,639,038	64.6% [6]	8,164,818
Italy	6,021	17,652	12,968,521	43.0% [7]	5,576,464
France	5,696	15,485	12,674,444	60.0% [8]	7,604,666
Spain	3,455	11,122	10,279,808	74.7% [9]	7,676,961
Australia	1,799	5,722	4,636,304	54.2% [10]	2,512,877
TOTAL	123,840	373,771	438,705,684	57.9% av	243,131,475



potential to reach
~243M women every 1-2y
across 9 major markets

Link to references slide; OC Screening every 1 – 2 years in accordance with clinical guidelines in each country

INOVIQ

Diagnostic Deals| Liquid biopsy platforms

	Acquiror / Licensee	Target / Licensor	Date	Deal Type	Stage	Upfront (US$m)	Milestones (US$m)	Total Deal Value (US$m)	Technology
1	Abbott	EXACT SCIENCES	2025	Acquisition	Commercial	N/A	N/A	$23,000	Various oncology screening, detection, monitoring and risk profile tests, $3.2B revenues expected 2025
2	Roche	Freenome	2025	Exclusive Development & Distribution, ex-US	Clinical	$75 (equity)	undiscl.	>$200	Kit-based versions of Freenome's centralised tests, exploring incorporation of Roche's multiomics tech
3	EXACT SCIENCES	Freenome	2025	Exclusive Licence, US	FDA Approval Pending	$75	$700	$885	Blood-based colorectal cancer screening assay, detects methylation signatures in ctDNA
5	Quest Diagnostics	HAYSTACK ONCOLOGY	2023	Acquisition	Clinical	$300	$150	$450	ctDNA liquid biopsy technology platform
6	labcorp	PGDx	2022	Acquistion	Clinical	$450	$125	$575	Cancer genomics technology and portfolio
7	Roche	freenome	2022	Equity stake	Clinical	undiscl.	undiscl.	$360	Blood-based multimodal cancer detection technology and colorectal cancer screening test in FDA pivotal PREEMPT CRC study
8	NEO GENOMICS	Inivata	2021	Acquisition	Clinical	$25	undiscl.	$200	Liquid biopsy technology platform including RaDaR MRD assay in development
9	Agilent	RESOLUTION BIOSCIENCE	2021	Acquisition	Clinical	$550	$145	$695	NGS-based liquid biopsy technology platform and CLIA lab
10	biotechne	exosomedx	2018	Acquisition	Commercial	$250	$325	$575	ExosomeDx technology platform and in-market (LDT) ExoDx Prostate Test

See Appendix for Deal References

CAR-Exosomes| Cost-effective process compared to Cell Therapy

Cell Therapy → *next generation* → **CAR-Exosome Therapy**





Autologous CAR-T therapy costs ~US$500k per dose; CAR-Exosome therapy expected to be significantly lower

CAR-Exosomes| Targeted therapy for Triple-Negative Breast Cancer

- **Lacks key targets:** TNBC does not express ER, PR or HER2, making it unresponsive to hormone or HER2-targeted therapies
- **Limited treatment options:** Chemotherapy (anthracyclines, taxanes, platinum agents) remains the standard of care, with few alternatives
- **High recurrence risk:** Initial chemo response is common, but resistance often develops, leading to relapse and poor prognosis
- **Unmet need:** Effective targeted therapies are needed to improve treatment outcomes and survival rates
- **CAR-NK-EVs are a potential next-gen cell-free therapy for TNBC:**
  - ✓ **In vitro PoC achieved:** CAR-NK-EVs induced 88% cell death in TNBC cells (Hs 578T) & validated at Peter Mac[1]
  - ✓ **In vivo PoC achieved:** CAR-NK-EVs demonstrated excellent anti-tumour efficacy & safety in TNBC mouse model[2]



Figure: CAR-NK-EVs **killed 88% of cells** in two aggressive cancers *in vitro*: **Triple Negative Breast Cancer** (TNBC) and **Non-Small Cell Lung Cancer** (NSCLC) within 96 hours

TNBC = Triple-Negative Breast Cancer; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; PoC = Proof of Concept;
1. CAR-NK-EV in vitro PoC (ASX: 18/6/25 & 22/9/25); 2. CAR-NK-EV in vivo PoC (ASX: 22/12/25)

CAR-Exosomes| Therapeutic development path



- ✓Research cell banks established
- ✓**Cells engineered with CARs**
- ✓**High purity & yield of CAR-EVs**
- ✓Scalable EXO-ACE EV isolation process
- ✓*In vitro* PoC for **CAR-T-EVs** in BC cells
- ✓*In vitro* PoC for **CAR-NK-EVs** in TNBC cells
- ✓*In vitro* tumour killing activity in TNBC cells confirmed at Peter Mac
- ✓*In vivo* efficacy data in TNBC mouse model **Dec 2025**
- ❑ Proprietary immune cell immortalisation
- ❑ Preclinical studies in BC and OC
- ❑ Commence IND-enabling studies

EXO-ACE data (ASX: 20/3/24 & 3/6/24); CAR-Exosome in vitro data (ASX: 18/6/24, 16/12/24 & 22/9/25)

INOVIQ

Therapeutic Deals| Exosome & cell therapies

	Acquirer / Licensee	Target / Licensor	Date	Deal Type	Stage	Upfront (US$m)	Milestones (US$m)	Total Deal Value (US$m)	Cell Source
1	Lilly	ORNA	2026	Acquisition	Preclinical	$2,400	N/A	$2,400	in vivo CAR
2	Bristol Myers Squibb	ORBITAL THERAPEUTICS	2025	Acquisition	Preclinical	$1,500	N/A	$1,500	in vivo CAR
3	Kite A GILEAD Company	interius	2025	Acquisition	Phase 1	$350	$0	$350	in vivo CAR
4	abbvie	capstantx	2025	Acquisition	Phase 1	$2,100	$0	$2,100	in vivo CAR
5	AstraZeneca	EsoBiotec	2025	Acquisition	Phase 1	$425	$575	$1,000	in vivo CAR
6	Roche	POSEIDA THERAPEUTICS	2024	Acquisition	Phase 1	$1,038	$462	$1,500	T cell
7	AstraZeneca	GRACELL	2023	Acquisition	Phase 1b	$1,000	$200	$1,200	T cell
8	Roche	POSEIDA THERAPEUTICS	2022	Research Collaboration & Licence	Phase 1	$110	$110	$220	T cell
9	Athenex	kuur THERAPEUTICS	2021	Acquisition	Phase 1	$70	$115	$185	iNKT cell
10	Takeda	Carmine THERAPEUTICS	2020	Research Collaboration & Option	Preclinical	Undisclosed	$900	$900	RBC-EV
11	Lilly	evox	2020	Research Collaboration & Licence	Preclinical	$20	Undisclosed	$1,200	EV
12	Takeda	evox	2020	Research Collaboration & Licence	Preclinical	$44	$838	$882	EV

Indicative, not exhaustive. See Appendix for Deal References

References| Ovarian Cancer in 9 Major Markets

1. United Nations, Data Portal, Population Division, 2024 data
2. The Lancet, Volume 55, Special Issue 101426, February 2025
3. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021, CDC, https://www.cdc.gov/pcd/issues/2023/23_0071.htm
4. Cancers (Basel). 2024 May 5;16(9):1783. doi: 10.3390/cancers16091783
5. Mammographie Screening Programm (DE)
6. NHS England, 30 Jan 2024
7. All.Can, 16 Feb 2024 https://www.all-can.org/news/latest-news/all-can-italy-press-release/
8. Cancer Epidemiology, vol 81, December 2022, 102270
9. Healthcare 2023, 11, 2934. https://doi.org/10.3390/healthcare11222934
10. National Cancer Control Indicators, Cancer Australia, https://ncci.canceraustralia.gov.au/screening/breast-screening-rates/breast-screening-rates
11. Assumes testing annually based on 2025 NCCN breast screening guidelines, https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf

References| Diagnostic & therapeutic deals

Diagnostic deals| Liquid biopsy platforms

1. Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision, 20 November 2025
2. Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S., 18 November 2025
3. Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests, 6 August 2025
4. Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio, 27 April 2023
5. Labcorp Completes Acquisition of PGDx, 15 Mar 2022
6. Blood Stake: Roche Raises Freenome Investment to $360M, 19 Jan, 2022
7. NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform, 05 May 2021
8. Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics, 03 March 2021
9. Bio-techne to acquire exosome diagnostics inc., 5 June 2018

Therapeutic deals| Exosome and cell therapies

1. Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company
2. Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
3. Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform | Interius, 21 August 2022
4. AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology , Jun 30, 2025
5. AstraZeneca to acquire EsoBiotec to advance cell therapy ambition, 17 Mar 2025
6. Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies, 26 November 2024
7. AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases, 26 December 2023
8. Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies, 3 August 2022
9. Athenex to Acruire Kurr Therapetics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform, 4 May 2021
10. Carmine Therapeutics & Takeda Collaborate to Develop Novel Non-viral Gene Therapies, 30 June 2020
11. Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly, 9 June 2020
12. Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration, 26 Mar 2020

INOVIQ